We have been examining the association of drug use (aspirin, statin, etc.) with incidence and consequence of colorectal cancer subtypes defined by tumor molecular and immune characteristics. This area is interface of pharmacoepidemiology and MPE (molecular pathological epidemiology), which potentially has high clinical and public health impacts. However, traditionally, this type of integrated analysis of drug exposures and tumor characteristics has not been a main part of pharmacoepidemiology. Therefore, we coined the term “pharmaco-MPE”, to not only stimulate this area of investigation but also increase awareness of people about this open evolving field for their career choices. The Pharmaco-MPE framework and approach can help us achieve “precision medicine, precision prevention, and precision public health”.
The first review on pharmaco-MPE!
Ogino S et al. npj Precis Oncol 2017
We have done influential studies in this phamarco-MPE field. Some research highlights are:
Chan AT et al. N Engl J Med 2007 (aspirin and incidence of colorectal cancer subtypes by tumor PTGS2 (cyclooxygenase 2) expression status)
Chan AT et al. JAMA 2009 (aspirin and mortality of colorectal cancer subtypes by tumor PTGS2 (cyclooxygenase 2) expression status)
Liao X et al. N Engl J Med 2012 (aspirin and incidence of colorectal cancer subtypes by tumor PIK3CA mutation status)
Nishihara R et al. JAMA 2013 (aspirin and incidence of colorectal cancer subtypes by tumor BRAF mutation status)
Fink SP et al. Sci Transl Med 2014 (aspirin and incidence of colorectal cancer subtypes by HPGD (15-PDGH) expression level in adjacent normal colon mucosa)
T Hamada et al. (J Clin Oncol 2017) have shown that regular aspirin use after cancer diagnosis is associated with lower mortality of colorectal cancer with lower-level CD274 (PD-L1, PDCD1 ligand 1) expression. This study also used the approach of “immuno-MPE“.
www.ncbi.nlm.nih.gov/pubmed/28406723
Y Cao et al. (Gastroenterology 2016) have shown that regular aspirin use is associated with lower risk of colorectal cancer with low-level tumor-infiltrating lymphocytes (TILs). This study also used the approach of “immuno-MPE“.
www.ncbi.nlm.nih.gov/pubmed/27475305
